
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
PFE | NYSE | USD | Real-time | |
PFE | Mexico | MXN | Delayed | |
PFE | TradeGate | EUR | Delayed | |
PFE | Frankfurt | EUR | Delayed | |
PFE | Xetra | EUR | Delayed | |
PFE | Hamburg | EUR | Delayed | |
PFE | Santiago | USD | Delayed | |
PFE | Buenos Aires | ARS | Delayed | |
PFIZ34 | BM&FBovespa | BRL | Delayed | |
PFE | Vienna | EUR | Delayed | |
PFE_KZ | KASE | USD | Delayed | |
PFE | Colombia | COP | Delayed | |
PFE | Lima | USD | Delayed |
Pfizer Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 100,330 million compared to USD 81,288 million a year ago. Net income was USD 31,372 million compared to USD 21,979 million a year ago. Basic earnings per share from continuing operations was USD 5.59 compared to USD 4 a year ago. Diluted earnings per share from continuing operations was USD 5.47 compared to USD 3.93 a year ago. Basic earnings per share was USD 5.59 compared to USD 3.92 a year ago. Diluted earnings per share was USD 5.47 compared to USD 3.85 a year ago.
Period Ending: | Dec 31, 2022 | Oct 02, 2022 | Jul 03, 2022 | Apr 03, 2022 |
---|---|---|---|---|
Total Revenue | 24290 | 22638 | 27742 | 25661 |
Gross Profit | 14299 | 16601 | 19572 | 15707 |
Operating Income | 5699 | 10149 | 12739 | 10352 |
Net Income | 4994 | 8608 | 9906 | 7864 |
Period Ending: | Dec 31, 2022 | Oct 02, 2022 | Jul 03, 2022 | Apr 03, 2022 |
---|---|---|---|---|
Total Assets | 197205 | 195350 | 195290 | 183841 |
Total Liabilities | 101288 | 102460 | 107821 | 101156 |
Total Equity | 95917 | 92890 | 87469 |
Period Ending: | Dec 31, 2022 | Oct 02, 2022 | Jul 03, 2022 | Apr 03, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 8582 | 5974 | 6541 | |
Cash From Investing Activities | -4410 | -627 | 567 | |
Cash From Financing Activities | -5015 | -5761 | -6578 | |
Net Change in Cash | -869 | -487 | 529 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review